Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMAD A CHERRY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1386690840
CMS profile
153038
Location
MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$35,380.13

197 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMAD A CHERRY

NPI 1386690840 · CMS profile ID 153038

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386690840?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMAD A CHERRY, NPI 1386690840, CMS profile ID 153038. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386690840?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOHAMAD A CHERRY, NPI 1386690840, CMS profile ID 153038. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386690840?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOHAMAD A CHERRY, NPI 1386690840, CMS profile ID 153038, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1386690840?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

197 matching records · $35,380.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 197 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 197.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Agios Pharmaceuticals, Inc. $18.3409/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253246222 CMS
AstraZeneca Pharmaceuticals LP $18.4909/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206160550 CMS
GENZYME CORPORATION $15.1309/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233408757 CMS
Eisai Inc. $15.9109/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500404 CMS
Eisai Inc. $2.8509/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500408 CMS
Daiichi Sankyo Inc. $24.8609/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197026683 CMS
Janssen Biotech, Inc. $13.7509/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175196197 CMS
Kite Pharma, Inc. $109.3809/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212087645 CMS
Novartis Pharmaceuticals Corporation $14.1109/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200198507 CMS
Incyte Corporation $19.0009/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226179394 CMS
Syndax Pharmaceuticals, Inc. $61.1209/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238990454 CMS
Syndax Pharmaceuticals, Inc. $100.9909/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238990456 CMS
Syndax Pharmaceuticals, Inc. $3,301.2509/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238990458 CMS
Syndax Pharmaceuticals, Inc. $256.7509/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238990460 CMS
E.R. Squibb & Sons, L.L.C. $17.5009/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184465254 CMS
PFIZER INC. $19.0009/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229449789 CMS
Daiichi Sankyo Inc. $18.8309/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197023427 CMS
EMD Serono, Inc. $15.2109/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236895877 CMS
PharmaEssentia USA Corporation $18.7909/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246830492 CMS
Daiichi Sankyo Inc. $15.0108/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197022759 CMS
PFIZER INC. $17.5808/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229289128 CMS
E.R. Squibb & Sons, L.L.C. $3,342.5008/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184465244 CMS
Incyte Corporation $18.7508/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226168891 CMS
Janssen Biotech, Inc. $18.3208/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175194388 CMS
Eisai Inc. $18.3208/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500402 CMS
Daiichi Sankyo Inc. $26.0408/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197015915 CMS
Janssen Biotech, Inc. $17.4008/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175195149 CMS
E.R. Squibb & Sons, L.L.C. $15.5608/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184465248 CMS
E.R. Squibb & Sons, L.L.C. $16.9408/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184465246 CMS
Gilead Sciences, Inc. $20.8508/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234519589 CMS
GlaxoSmithKline, LLC. $18.6708/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191025164 CMS
Daiichi Sankyo Inc. $19.7308/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197015641 CMS
ARRAY BIOPHARMA INC $16.3408/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229054404 CMS
Cumberland Pharmaceuticals, Inc. $19.0008/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242137980 CMS
Agios Pharmaceuticals, Inc. $18.4007/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253244850 CMS
PFIZER INC. $15.6007/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229162290 CMS
Merck Sharp & Dohme LLC $15.1307/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238318232 CMS
GENZYME CORPORATION $21.7207/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233408779 CMS
Kerecis Limited $59.3507/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243696025 CMS
E.R. Squibb & Sons, L.L.C. $15.5607/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184465242 CMS
AstraZeneca Pharmaceuticals LP $13.4807/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206326311 CMS
Celgene Corporation $4.7407/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223255762 CMS
Daiichi Sankyo Inc. $15.0007/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197084301 CMS
Eisai Inc. $17.6507/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500400 CMS
Janssen Biotech, Inc. $18.3307/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175195259 CMS
Daiichi Sankyo Inc. $18.5707/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197101857 CMS
Kite Pharma, Inc. $14.9607/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212087639 CMS
Gilead Sciences, Inc. $16.5107/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234561791 CMS
Astellas Pharma US Inc $18.1707/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238642819 CMS
EMD Serono, Inc. $18.9506/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236877629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,160.81 159
PY2020 $21,530.40 69
PY2021 $17,925.93 88
PY2022 $56,509.54 227
PY2023 $40,094.05 221
PY2024 $43,028.37 226
PY2025 $35,380.13 197

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $274,990.86 20
PY2024 Principal investigator $154,051.74 20
PY2023 Principal investigator $29,821.11 4
PY2022 Recipient $438.23 2
PY2022 Principal investigator $78,886.97 4
PY2021 Principal investigator $334,156.75 8
PY2020 Recipient $1,304.22 7
PY2020 Principal investigator $464,853.58 9
PY2019 Recipient $1,995.52 1
PY2019 Principal investigator $293,174.40 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $4,817.30 12/31/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609758
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,290.75 11/26/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1236000542
Principal investigator 1 PFIZER INC. $3,593.00 11/25/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228712034
Principal investigator 1 Sumitomo Pharma America, Inc. $225.00 11/13/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609754
Principal investigator 1 Sumitomo Pharma America, Inc. $225.00 10/23/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609746
Principal investigator 1 Sumitomo Pharma America, Inc. $225.00 10/23/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609750
Principal investigator 1 Sumitomo Pharma America, Inc. $743.00 08/14/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609742
Principal investigator 1 Celgene Corporation $39,860.00 06/19/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, open-label, single arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 (lisocabtagene maraleucel) in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin Lymphoma (NHL) No dispute reported 06/30/2026 1222305298
Principal investigator 1 Celgene Corporation $4,361.00 06/12/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. No dispute reported 06/30/2026 1222305430
Principal investigator 1 Sumitomo Pharma America, Inc. $743.00 05/15/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609739
Principal investigator 1 Sumitomo Pharma America, Inc. $743.00 05/01/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609736
Principal investigator 1 Sumitomo Pharma America, Inc. $3,266.00 04/24/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609731
Principal investigator 1 Celgene Corporation $3,500.00 03/14/2025 Non-covered Recipient Entity
Advarra
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222306945
Principal investigator 1 Sumitomo Pharma America, Inc. $583.00 02/27/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176609727
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $38,429.00 02/24/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1236000540
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,185.83 01/27/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1236000538
Principal investigator 1 Celgene Corporation $2,000.00 01/24/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1222305368
Principal investigator 1 Celgene Corporation $27,721.00 01/24/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1222305422
Principal investigator 1 PFIZER INC. $2,000.00 01/24/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228801521
Principal investigator 1 Celgene Corporation $108,479.98 01/08/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222305328